Sanara MedTech (SMTI) Stock Price, News & Analysis

-0.30 (-0.91%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
11,772 shs
Average Volume
13,365 shs
Market Capitalization
$281.01 million
P/E Ratio
Dividend Yield
Price Target

Sanara MedTech MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
35.0% Upside
$44.00 Price Target
Short Interest
4.13% of Float Sold Short
Dividend Strength
News Sentiment
0.20mentions of Sanara MedTech in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.51 out of 5 stars

Medical Sector

668th out of 909 stocks

Surgical Appliances & Supplies Industry

14th out of 17 stocks

SMTI stock logo

About Sanara MedTech Stock (NASDAQ:SMTI)

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

SMTI Stock Price History

SMTI Stock News Headlines

The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
Sanara Medtech Inc (SMTI)
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
Sanara MedTech's Earnings: A Preview
CGI Cellerate RX, LLC's Net Worth
Sanara MedTech Inks Exclusive License Agreement With Tufts University
Sanara MedTech Inc. Announces Third Quarter 2023 Results
See More Headlines
Receive SMTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical appliances & supplies
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$64.99 million
Book Value
$5.22 per share


Free Float
Market Cap
$281.01 million
Not Optionable
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Ronald T. Nixon (Age 68)
    Executive Chairman
  • Mr. Zachary B. FlemingMr. Zachary B. Fleming (Age 49)
    Chief Executive Officer
    Comp: $593.64k
  • Mr. Michael D. McNeil (Age 59)
    CFO & Corporate Secretary
    Comp: $438.68k
  • Dr. Christopher A. Morrison FACHM (Age 54)
    FAPWCA, FCCWS, M.D., President of Telehealth Services
    Comp: $156k
  • Mr. Bill Fitzgerald
    Chief Compliance Officer
  • Ms. Tricia Matteson
    Vice President of Marketing
  • Mr. Tyler Palmer
    Chief Corporate Development & Strategy Officer
  • Dr. Rebecca Erin Mcmahon (Age 39)
    President of Research & Development
  • Mr. Seth Yon
    President of Commercial

SMTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Sanara MedTech stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanara MedTech in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SMTI shares.
View SMTI analyst ratings
or view top-rated stocks.

What is Sanara MedTech's stock price target for 2024?

1 Wall Street research analysts have issued 1 year target prices for Sanara MedTech's stock. Their SMTI share price targets range from $44.00 to $44.00. On average, they anticipate the company's share price to reach $44.00 in the next twelve months. This suggests a possible upside of 35.0% from the stock's current price.
View analysts price targets for SMTI
or view top-rated stocks among Wall Street analysts.

How have SMTI shares performed in 2024?

Sanara MedTech's stock was trading at $41.10 at the beginning of the year. Since then, SMTI shares have decreased by 20.7% and is now trading at $32.60.
View the best growth stocks for 2024 here

When is Sanara MedTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SMTI earnings forecast

How were Sanara MedTech's earnings last quarter?

Sanara MedTech Inc. (NASDAQ:SMTI) released its quarterly earnings results on Monday, March, 25th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $17.69 million for the quarter. Sanara MedTech had a negative net margin of 6.62% and a negative trailing twelve-month return on equity of 11.12%.

What guidance has Sanara MedTech issued on next quarter's earnings?

Sanara MedTech issued an update on its fourth quarter 2023 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $17.7 million-$17.7 million, compared to the consensus revenue estimate of $16.5 million.

What other stocks do shareholders of Sanara MedTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanara MedTech investors own include Lakeland Industries (LAKE), Ovintiv (OVV), SIG (SHI), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), American Airlines Group (AAL), Abbott Laboratories (ABT), AC Immune (ACIU) and Applied Genetic Technologies (AGTC).

How do I buy shares of Sanara MedTech?

Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SMTI) was last updated on 4/23/2024 by Staff

From Our Partners